9 results about "Osteoarthritic cartilage" patented technology

The invention discloses HA-PAS hydrogel for enhancing cartilage repair of early osteoarthritis and a preparation method of the HA-PAS hydrogel. According to the hydrogel, formylated hyaluronic acid, hydrazide modified low-methoxyl pectin and phenylboronic acid modified alginate form a ternary polysaccharide skeleton, a double-dynamic cross-linked network is formed through acylhydrazone bonds and boric acid ester bonds, and a triple network structure is formed by combining permanent cross-linking catalyzed by horse radish peroxidase. The hydrogel integrates functional components such as nano-selenium, a pulullan-strontium chelate and a mesenchymal stem cell source exosome, so that multiple effects of resisting oxidation, resisting inflammation, promoting cartilage differentiation and repairing subchondral bones are achieved. The compression modulus of the hydrogel is 0.8-1.5 MPa, and the hydrogel can be injected for in-situ gelling and MMP responsive degradation, shows an excellent cartilage repair effect in animal experiments, and provides a new solution for treatment of early osteoarthritis.

The application discloses a construction method and application of an osteoarthritis cartilage organoid, and the method comprises the following steps: 1) mesenchymal stem cells are inoculated on a round bottom culture plate by a Micromass method, and are cultured in a chondrogenic induction culture medium containing dexamethasone, ascorbic acid and TGF-beta 3 for 10-18 days to form a transparent cartilage organoid; and 2) the transparent cartilage organoid is placed in an osteoarthritis induction culture medium containing dexamethasone, L-thyroxine, inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and beta-glycerophosphate sodium for continuous culture for 5-10 days to obtain an osteoarthritis cartilage organoid; the model simultaneously presents multi-dimensional pathological characteristics such as matrix degeneration, hypertrophy, inflammation activation and vascularization trend, and can be used for osteoarthritis pathogenesis research, drug screening and cell treatment effect evaluation; the construction method is controllable and has good repeatability, and provides a reliable three-dimensional in-vitro model for osteoarthritis research.

This invention relates to the field of biomedical materials, providing non-denatured type II collagen ultrafine powder with cartilage tissue-targeted growth and structural repair functions, its bioactivity preservation preparation method, and its application in joints. The ultrafine powder has an average particle size of 0.5-50 μm, a triple helix structure integrity rate of not less than 85%, a thermal denaturation temperature of 38-48℃, and retains chondrocyte binding domains CB10, CB11, and MMP cleavage sites. The preparation method includes raw material pretreatment, time-limited enzymatic hydrolysis, graded purification, and ultra-low temperature ball milling. The product can be used for the repair and treatment of cartilage degenerative diseases such as osteoarthritis and cartilage damage.

The invention provides hydrogel loaded with rhizoma drynariae extracellular vesicles as well as a preparation method and application of the hydrogel, and belongs to the technical field of biological medicines. The novel bone biological material is creatively prepared by compounding rhizoma drynariae extracellular vesicles with methacryloyl gelatin, and is subjected to performance and characterization detection and research to find that the novel bone biological material is good in forming performance, high in bioavailability, good in microstructure and physical and chemical properties, and capable of repairing osteoarthritis cartilage injury, and has a good application prospect. The polypeptide is proved to have the potential of efficiently, slowly and accurately treating osteoarthritis, and can be applied to treating osteoarthritis and repairing cartilage injury.

The invention provides application of solanine encapsulated by an MOF (Metal Organic Framework) material in preparation of a medicine for preventing and treating osteoarthritis. The preparation method of the solanine encapsulated by the MOF material comprises the following steps: mixing and stirring UIO-66-NH2, DI-water and solanine to obtain a solution A; preparing a polyethyleneimine aqueous solution as a solution B; and adding the solution B into the solution A, and continuously stirring to obtain the MOF material encapsulated solanine USP. The MOF material encapsulated solanine material prepared in the invention can obviously alleviate inflammatory response and prevent cartilage cell ferroptosis progress, and provides new feasibility for treatment of osteoarthritis cartilage cell ferroptosis.

The invention relates to the technical field of medical data detection, in particular to an osteoarthritis intra-cartilage ossification image recognition method, which realizes accurate recognition of osteoarthritis intra-cartilage ossification. The method comprises the following steps: acquiring a cell sample, detecting degeneration, hypertrophy and IL-33 expression of cartilage cells through reverse transcription-polymerase chain reaction, performing hypertrophy induction on the cells, and comparing ossification conditions. Fluid shear force equipment is further utilized to simulate an in-vivo mechanical environment, the cartilage cell hypertrophy degree is evaluated, and multi-dimensional data are obtained through pathological sections, immunohistochemistry and tomography. And finally, acquiring an articular cartilage image of the old people by utilizing a 9.4 T magnetic resonance imaging technology, and obtaining an articular cartilage and subchondral ossification analysis result of the old people in combination with the trained osteoarthritis intra-cartilage ossification image analysis model. According to the method, the accuracy and efficiency of osteoarthritis identification are improved, and powerful support is provided for early prevention and treatment of osteoarthritis.

The application relates to the field of geriatric treatment, in particular to application of a matrix metalloproteinase inhibitor, MSAB or a pharmaceutically acceptable salt thereof, in preparation of a medicine for preventing or treating osteoarthritis cartilage injury. The application adopts the MSAB to inhibit expression of matrix metalloproteinase in chondrocytes, reduces destruction of joint cartilage structure, and achieves the effect of preventing or treating osteoarthritis.

The invention relates to the technical field of biological medicines, and provides application of MybpC1 gene / protein in preparation of osteoarthritis medicines. The invention proves that the expression of the MybpC1 gene / protein in osteoarthritis cartilage cells is obviously reduced, the expression level of related protein of osteoarthritis progress is related to the expression level of MybpC1, and the progress of osteoarthritis of a mouse can be relieved by injecting MybpC1 overexpressed lentivirus into an articular cavity of the mouse with osteoarthritis. Therefore, the MybpC1 gene / protein can be used as a drug target, and has a good prospect in screening and preparing drugs for treating osteoarthritis.

The invention discloses application of circCRIM1 in regulation and control of cartilage cell differentiation and cartilage homeostasis, and relates to the technical field of gene engineering. The invention discloses an application of circCRIM1 in regulation and control of cartilage cell differentiation and cartilage homeostasis. A nucleotide sequence of the circCRIM1 is shown as SEQ. ID. NO.1; experiments prove that circCRIM1 is highly expressed in osteoarthritis cartilage, and the inhibition effect of circCRIM1 on MMP16 is relieved through specific binding of circCRIM1 to miR-320c, so that cartilage generation of human adipose-derived stem cells is inhibited, cartilage cell homeostasis is destroyed, and cartilage matrix degradation is promoted. Based on the mechanism, the invention can provide a new target and strategy for clinically and effectively delaying the progress of osteoarthritis and treating osteoarthritis.